297 related articles for article (PubMed ID: 27278751)
41. A targeting drug delivery system for ovarian carcinoma: transferrin modified lipid coated paclitaxel-loaded nanoparticles.
Li R; Zhang Q; Wang XY; Chen XG; He YX; Yang WY; Yang X
Drug Res (Stuttg); 2014 Oct; 64(10):541-7. PubMed ID: 24443309
[TBL] [Abstract][Full Text] [Related]
42. Inducing Optimal Antitumor Immune Response through Coadministering iRGD with Pirarubicin Loaded Nanostructured Lipid Carriers for Breast Cancer Therapy.
Deng C; Jia M; Wei G; Tan T; Fu Y; Gao H; Sun X; Zhang Q; Gong T; Zhang Z
Mol Pharm; 2017 Jan; 14(1):296-309. PubMed ID: 27936775
[TBL] [Abstract][Full Text] [Related]
43. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis.
Roger E; Lagarce F; Garcion E; Benoit JP
J Control Release; 2009 Dec; 140(2):174-81. PubMed ID: 19699246
[TBL] [Abstract][Full Text] [Related]
44. Development and in vitro characterization of paclitaxel and docetaxel loaded into hydrophobically derivatized hyperbranched polyglycerols.
Mugabe C; Liggins RT; Guan D; Manisali I; Chafeeva I; Brooks DE; Heller M; Jackson JK; Burt HM
Int J Pharm; 2011 Feb; 404(1-2):238-49. PubMed ID: 21093563
[TBL] [Abstract][Full Text] [Related]
45. Well-Defined Redox-Sensitive Polyethene Glycol-Paclitaxel Prodrug Conjugate for Tumor-Specific Delivery of Paclitaxel Using Octreotide for Tumor Targeting.
Yin T; Wu Q; Wang L; Yin L; Zhou J; Huo M
Mol Pharm; 2015 Aug; 12(8):3020-31. PubMed ID: 26086430
[TBL] [Abstract][Full Text] [Related]
46. Novel free-paclitaxel-loaded redox-responsive nanoparticles based on a disulfide-linked poly(ethylene glycol)-drug conjugate for intracellular drug delivery: synthesis, characterization, and antitumor activity in vitro and in vivo.
Chuan X; Song Q; Lin J; Chen X; Zhang H; Dai W; He B; Wang X; Zhang Q
Mol Pharm; 2014 Oct; 11(10):3656-70. PubMed ID: 25208098
[TBL] [Abstract][Full Text] [Related]
47. Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo.
Lu J; Chuan X; Zhang H; Dai W; Wang X; Wang X; Zhang Q
Int J Pharm; 2014 Aug; 471(1-2):525-35. PubMed ID: 24858391
[TBL] [Abstract][Full Text] [Related]
48. Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621.
Danhier F; Ucakar B; Magotteaux N; Brewster ME; Préat V
Int J Pharm; 2010 Jun; 392(1-2):20-8. PubMed ID: 20226846
[TBL] [Abstract][Full Text] [Related]
49. Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy.
Huo M; Zhu Q; Wu Q; Yin T; Wang L; Yin L; Zhou J
J Pharm Sci; 2015 Jun; 104(6):2018-2028. PubMed ID: 25820241
[TBL] [Abstract][Full Text] [Related]
50. Nanoprodrug of retinoic acid-modified paclitaxel.
Zhou Z; Yan J; Sun T; Wang X; Xie Z
Org Biomol Chem; 2017 Nov; 15(45):9611-9615. PubMed ID: 29106434
[TBL] [Abstract][Full Text] [Related]
51. iRGD-decorated reduction-responsive nanoclusters for targeted drug delivery.
Hu H; Wan J; Huang X; Tang Y; Xiao C; Xu H; Yang X; Li Z
Nanoscale; 2018 Jun; 10(22):10514-10527. PubMed ID: 29799599
[TBL] [Abstract][Full Text] [Related]
52. The antiangiogenic efficacy of NGR-modified PEG-DSPE micelles containing paclitaxel (NGR-M-PTX) for the treatment of glioma in rats.
Zhao BJ; Ke XY; Huang Y; Chen XM; Zhao X; Zhao BX; Lu WL; Lou JN; Zhang X; Zhang Q
J Drug Target; 2011 Jun; 19(5):382-90. PubMed ID: 20677914
[TBL] [Abstract][Full Text] [Related]
53. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance.
Liu Y; Pan J; Feng SS
Int J Pharm; 2010 Aug; 395(1-2):243-50. PubMed ID: 20472049
[TBL] [Abstract][Full Text] [Related]
54. Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer.
Wang F; Li L; Liu B; Chen Z; Li C
Biomed Pharmacother; 2017 Feb; 86():595-604. PubMed ID: 28027535
[TBL] [Abstract][Full Text] [Related]
55. Cooperative dual-activity targeted nanomedicine for specific and effective prostate cancer therapy.
Yang HW; Hua MY; Liu HL; Tsai RY; Chuang CK; Chu PC; Wu PY; Chang YH; Chuang HC; Yu KJ; Pang ST
ACS Nano; 2012 Feb; 6(2):1795-805. PubMed ID: 22248493
[TBL] [Abstract][Full Text] [Related]
56. Paclitaxel-loaded solid lipid nanoparticles modified with Tyr-3-octreotide for enhanced anti-angiogenic and anti-glioma therapy.
Banerjee I; De K; Mukherjee D; Dey G; Chattopadhyay S; Mukherjee M; Mandal M; Bandyopadhyay AK; Gupta A; Ganguly S; Misra M
Acta Biomater; 2016 Jul; 38():69-81. PubMed ID: 27109765
[TBL] [Abstract][Full Text] [Related]
57. Preparation and in vitro properties of redox-responsive polymeric nanoparticles for paclitaxel delivery.
Song N; Liu W; Tu Q; Liu R; Zhang Y; Wang J
Colloids Surf B Biointerfaces; 2011 Oct; 87(2):454-63. PubMed ID: 21719259
[TBL] [Abstract][Full Text] [Related]
58. Paclitaxel-loaded polymeric micelles based on poly(ɛ-caprolactone)-poly(ethylene glycol)-poly(ɛ-caprolactone) triblock copolymers: in vitro and in vivo evaluation.
Zhang L; He Y; Ma G; Song C; Sun H
Nanomedicine; 2012 Aug; 8(6):925-34. PubMed ID: 22101107
[TBL] [Abstract][Full Text] [Related]
59. Effects of paclitaxel nanocrystals surface charge on cell internalization.
Choi JS; Park JS
Eur J Pharm Sci; 2016 Oct; 93():90-6. PubMed ID: 27516149
[TBL] [Abstract][Full Text] [Related]
60. Magnetic core-shell nanocapsules with dual-targeting capabilities and co-delivery of multiple drugs to treat brain gliomas.
Fang JH; Lai YH; Chiu TL; Chen YY; Hu SH; Chen SY
Adv Healthc Mater; 2014 Aug; 3(8):1250-60. PubMed ID: 24623647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
